Language:

Efficacy and safety of single-dose dexamethasone implantation for patients with persistent diabetic macular edema: a systematic review and meta-analysis

Graefe's archive for clinical and experimental ophthalmology, 2022-02, Vol.260 (2), p.405-413 [Peer Reviewed Journal]

The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 ;2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. ;The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021. ;ISSN: 0721-832X ;EISSN: 1435-702X ;DOI: 10.1007/s00417-021-05369-9 ;PMID: 34550419

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Efficacy and safety of single-dose dexamethasone implantation for patients with persistent diabetic macular edema: a systematic review and meta-analysis
Author: Yuan, Qiongzhen ; Liu, Yilin ; Xu, Hanyue ; Gao, Yunxia ; Qin, Ling ; Gou, Yueqin ; Tao, Mengying ; Zhang, Ming
Subjects: Acuity ; Clinical trials ; Dexamethasone ; Dexamethasone - therapeutic use ; Diabetes ; Diabetes Mellitus ; Diabetic Retinopathy - diagnosis ; Diabetic Retinopathy - drug therapy ; Drug Implants - therapeutic use ; Edema ; Glucocorticoids - therapeutic use ; Humans ; Intravitreal Injections ; Macular Edema - diagnosis ; Macular Edema - drug therapy ; Macular Edema - etiology ; Medicine ; Medicine & Public Health ; Meta-analysis ; Ophthalmology ; Patients ; Retrospective Studies ; Review Article ; Treatment Outcome ; Vascular endothelial growth factor ; Visual Acuity
Is Part Of: Graefe's archive for clinical and experimental ophthalmology, 2022-02, Vol.260 (2), p.405-413
Description: Purpose This meta-analysis was conducted to evaluate the efficacy and safety of single-dose dexamethasone implantation for treating persistent DME (diabetic macular edema) refractory to anti-VEGF (anti-vascular endothelial growth factor) drugs over a period of 6 months. Methods All related clinical trials were reviewed by searching electronic databases of PubMed, Medline, Web of Science, Cochrane Library, and EMBASE. The primary outcome parameters were best-corrected visual acuity (BCVA) and central macular thickness (CMT). We performed this meta-analysis by using Stata15.0. Results Ten clinical trials involving 362 eyes from 328 patients were eligible in the final analysis. After single-dose dexamethasone implantation, there was a significant improvement in BCVA from baseline to 1, 3, and 6 months with an average increase of − 0.15 logMAR ( p < 0.001), − 0.14 logMAR ( p < 0.001), and − 0.07 logMAR ( p = 0.004), respectively. Further, mean CMT decreased significantly with an average reduction of 249.18 μm ( p < 0.001), 217.66 μm ( p < 0.001), and 91.56 μm ( p < 0.001) at months 1, 3, and 6, respectively. Conclusions Our results indicate that switching to a dexamethasone implant could achieve significant anatomical and functional improvement among patients with refractory DME. Clinicians should be aware of this treatment option in refractory DME.
Publisher: Berlin/Heidelberg: Springer Berlin Heidelberg
Language: English
Identifier: ISSN: 0721-832X
EISSN: 1435-702X
DOI: 10.1007/s00417-021-05369-9
PMID: 34550419
Source: MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Efficacy and safety of single-dose dexamethasone implantation for patients with persistent diabetic macular edema: a systematic review and meta-analysis

Searching Remote Databases, Please Wait